What is claimed is:

~~1. An isolated anti-Epidermal Growth Factor Receptor (EGFR) antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166.~~

~~2. The isolated antibody according to claim 1, wherein said isolated antibody is in the form of an antibody F(ab')2, scFv fragment, diabody, triabody or tetrabody.~~

~~3. The isolated antibody according to claim 1, further comprising a detectable label.~~

~~4. The isolated antibody according to claim 3, wherein said detectable label is a radiolabel.~~

~~5. The isolated antibody according to claim 4, wherein said radiolabel is selected from the group consisting of $^{3}$H, $^{14}$C, $^{32}$P, $^{35}$S, $^{36}$Cl, $^{51}$Cr, $^{58}$Co, $^{59}$Fe, $^{90}$Y, $^{121}$I, $^{124}$I, $^{125}$I, $^{131}$I, $^{111}$In, $^{211}$At, $^{198}$Au, $^{67}$Cu, $^{225}$Ac, $^{213}$Bi, $^{99}$Tc and $^{186}$Re.~~

~~6. The isolated antibody according to claim 1, wherein said isolated antibody is pegylated.~~

~~7~~1. An isolated nucleic acid which comprises a sequence encoding ~~the~~ an isolated ~~antibody of claim 1~~ anti-Epidermal Growth Factor Receptor (EGFR) antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166.

~~8~~2. A method of preparing ~~the~~ an isolated ~~antibody according to claim 1,~~ anti-Epidermal Growth Factor Receptor (EGFR) monoclonal IgG antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID

NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, wherein the antibody is characterized by a single binding affinity for an antigen, comprising expressing a nucleic acid under conditions to bring about expression of said antibody, and recovering said antibody.

~~9~~3. A kit for the diagnosis of a tumor in which EGFR is aberrantly expressed or EGFR is expressed in the form of a truncated protein, comprising ~~the~~ an isolated ~~antibody of claim 1~~anti-Epidermal Growth Factor Receptor (EGFR) monoclonal IgG antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, wherein the antibody is characterized by a single binding affinity for an antigen, further comprising reagents and/or instructions for use.

~~10. The kit according to claim 9, further comprising reagents and/or instructions for use.~~

~~11~~4. A unicellular host transformed with a recombinant DNA molecule which encodes ~~the~~ an isolated ~~antibody of claim 1.~~ anti-Epidermal Growth Factor Receptor (EGFR) monoclonal IgG antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, wherein the antibody is characterized by a single binding affinity for an antigen.

~~12. A unicellular host transformed with a recombinant DNA molecule which encodes the isolated antibody of claim 1, wherein the unicellular host is selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeast, a mammalian cell, a plant cell, an insect cell, and a human cell in tissue culture.~~

~~13. The isolated antibody according to claim 1, wherein said heavy chain comprises the constant region set forth in SEQ ID NO: 43~~

~~14. The isolated antibody according to claim 1, wherein said light chain comprises the constant region set forth in SEQ ID NO: 48.~~

~~15. The isolated antibody according to claim 14, wherein the said antibody is an IgG isotype.~~

~~16. The isolated antibody according to claim 15, wherein the said IgG isotype is an IgG1 isotype.~~

~~17. A pharmaceutical composition comprising the isolated antibody according to claim 1.~~

~~18. The isolated antibody according to claim 1, conjugated to a cytotoxic agent.~~

~~19~~5. An immunoconjugate comprising an isolated anti-Epidermal Growth Factor Receptor (EGFR) monoclonal IgG antibody conjugated to a cytotoxic agent, wherein said antibody ~~is an IgG isotype,~~ comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, wherein the antibody is characterized by a single binding affinity for an antigen.

~~20~~6. The immunoconjugate of claim ~~19~~5, wherein said antibody comprises a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 48.

~~21~~7. The immunoconjugate of claim ~~19~~5, wherein said antibody is an IgG1 isotype.

~~22~~8. A pharmaceutical composition comprising the immunoconjugate according to claim ~~19~~5.

~~23~~9. The immunoconjugate of claim ~~19~~5, wherein said antibody comprises a kappa light chain.

~~24~~10. The isolated antibody of claim 1, wherein said antibody comprises a kappa light chain.

~~25. The unicellular host of claim 12, wherein said mammalian cell is selected from the group consisting of a Chinese Hamster Ovary (CHO) cell, a YB/20 cell, a NS0 cell, an SP2/0 cell, an R1.1 cell, a B-W cell, an L-M cell, a COS 1 cell, a COS 7 cell, a BSC1 cell, a BSC40 cell, and a BMT10 cell.~~

11. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 190.

12. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 41.

13. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 192.

14. The isolated nucleic acid of claim 13, wherein the nucleic acid further comprises a nucleotide sequence encoding an antibody heavy chain constant region.

15. The isolated nucleic acid of claim 14, wherein the antibody heavy chain constant region is an IgG1 constant region.

16. A recombinant expression vector comprising the nucleic acid of any one of claims 1 or 11 to 15.

17. A host cell comprising the recombinant expression vector of claim 16.

18. The host cell of claim 17, wherein the host cell is selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeasts, a mammalian cell, a plant cell, and an insect cell.

19. The host cell of claim 18, wherein the mammalian cell is selected from the group consisting of CHO, YB/20, NSO, SP2/0, R1.1, B-W, L-M,. COS1, COS7, BSC1, BSC40, and BMT10 cells, and a human cell.

20. A method of synthesizing an antibody that binds EGFR comprising culturing the host cell of claim 17 in a culture medium,

allowing expression from the nucleic acid, and

recovering the antibody.